CA2079007C - Activity controlled electrotransport drug delivery device - Google Patents
Activity controlled electrotransport drug delivery device Download PDFInfo
- Publication number
- CA2079007C CA2079007C CA002079007A CA2079007A CA2079007C CA 2079007 C CA2079007 C CA 2079007C CA 002079007 A CA002079007 A CA 002079007A CA 2079007 A CA2079007 A CA 2079007A CA 2079007 C CA2079007 C CA 2079007C
- Authority
- CA
- Canada
- Prior art keywords
- activity
- patient
- control signal
- current generator
- generating
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Lifetime
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61N—ELECTROTHERAPY; MAGNETOTHERAPY; RADIATION THERAPY; ULTRASOUND THERAPY
- A61N1/00—Electrotherapy; Circuits therefor
- A61N1/02—Details
- A61N1/04—Electrodes
- A61N1/0404—Electrodes for external use
- A61N1/0408—Use-related aspects
- A61N1/0428—Specially adapted for iontophoresis, e.g. AC, DC or including drug reservoirs
- A61N1/0432—Anode and cathode
- A61N1/044—Shape of the electrode
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61N—ELECTROTHERAPY; MAGNETOTHERAPY; RADIATION THERAPY; ULTRASOUND THERAPY
- A61N1/00—Electrotherapy; Circuits therefor
- A61N1/02—Details
- A61N1/04—Electrodes
- A61N1/0404—Electrodes for external use
- A61N1/0408—Use-related aspects
- A61N1/0428—Specially adapted for iontophoresis, e.g. AC, DC or including drug reservoirs
- A61N1/0448—Drug reservoir
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61N—ELECTROTHERAPY; MAGNETOTHERAPY; RADIATION THERAPY; ULTRASOUND THERAPY
- A61N1/00—Electrotherapy; Circuits therefor
- A61N1/18—Applying electric currents by contact electrodes
- A61N1/32—Applying electric currents by contact electrodes alternating or intermittent currents
- A61N1/325—Applying electric currents by contact electrodes alternating or intermittent currents for iontophoresis, i.e. transfer of media in ionic state by an electromotoric force into the body
Abstract
An iontophoretic drug delivery device includes a patient activity sensor (38) which is used to selectively deliver drugs based upon a measured physical activity of the patient. The activ-ity sensor (38) is mounted on a flexible circuit board (36), whose deflection communicate the patient's physical motion to the sen-sor.
Description
WO 91/15261 PCT/US9l/02160 ACTIVITY CONTROLLED ELECTROTRANSPORT DRUG DELIVERY DEVICE
Background of the Invention Field of the Invention The present invention relates to transdermal electrotransport drug administration devices and, more particularly, to a patch system which includes a current generator and a sensor for feedback control of the patients activity level to regulate the rate of drug delivery.
Description of the Prior Art Transdermal elctrotransport is a method of applying a medication to a patient l~hrough the application of an electromotive force to drive chemicals through the skin. The iontophoretic application of medicaments avoids many problems associated with the p~=_rcutaneous delivery of drugs. Experimentation has been directed to, development of drugs Jultable for electrot~an~pert and, to patch electrode systems suitable for dispensing those drugs.
In general, there are two major mechanisms for electrotransport. Iontophoresis refers to the transport of charged substances, which electroso:mosis refers to the transdermal flux of a liquid solvent (e. g., the liquid solvent containing the uncharged drug or agent) which is induced by the presence of an electric field imposed across the skin by the donor electrode. As used herein the terms "iontophoresis" and "iontoppheroetic" refer to either, the delivery of charged drugs or agents, the delivery of uncharged drugs or agents by the process of electroosmosis, or both.
The expressions "drug" and "therapeutic agent" are used interchangeably and are intended to have their broadest «~
interpretation as any therapeutically active substance which is delivered to a living organism to produce a desired, usually beneficial, effect. In general, this includes therapeutic agents in all of the major therapeutic areas including, but not limited to, anti-infectives such as antibiotics and antiviral agents, analgesics and analgesic combinations, anesthetics, anorexics, antiarthritics, antiasthmatic agents, anticonvulsants, antidepressants, antidiabetic agents, antidiarrheals, antihistamines, anti-inflammatory agents, antimigraine preparations, antimotion sickness preparations, antinauseants, antineoplastics, antiparkinsonism drugs, antipruritics, antipsychotics, antipyretics, antispasmodics, including gastrointestinal and urinary, anticholinergics, sympathomimetrics, xanthine derivatives, cardiovascular preparations including calcium channel blockers, beta-blockers, antiarrythmics, antihypertensives, diuretics, vasodilators, including general, coronary, peripheral and cerebral, central nervous system stimulants, cough and cold preparations, decongestants, diagnostics, hormones, hypnotics, immunosuppressives, muscle relaxants, parasympatholytics, parasympathomimetrics, proteins, peptides, psychostimulants, sedatives and tranquilizers.
The invention is also useful in the controlled delivery or peptides, polypeptides, proteins and other macromolecules. These macromolecular substances typically have a molecular weight of at least about 300 daltons, and more typically a molecular weight in the range of about 300 to 40,000 daltons. Specific examples of peptides and proteins in this size range include, without limitation, LHRH, LHRH analogs such as buserelin, gonadorelin, naphrelin and leuprolide, GHRH, insulin, heparin, calcitonin, endorphin, TRH, NT-36 (chemical name: N=[((s)-4oxo-2-azetidinyl]carbonyl]-L-hystidyl-L-prolinamide), liprecin, pituitary hormones (e. g., HGH, HMG, HCG, desmopressin ' aF , ''1 r ~~~ ~~~1~ 1 acetate, etc.), follicle luteoids, aANF, growth factor releasing factor (GFRF), QMSH, somatostatin, bradykinin, somatotropin, platelet-derived growth factor, asparaginase, bleomycin sulfate, chymopapain, cholecystokinin, chorionic gonadotropin, corticotropin (ACTH), erythropoietin, epoprostenol (platelet aggregation inhibitor), glucagon, hyaluronidase, interferon, interleuk.in-1, interleukin-2 menotropins (urofollitropin (FSH) and LH), oxytocin, streptokinase, tissue plasminogen activator, urokinase, vasopressin, ACTH analogs, ANP, ANP clearance inhibitors, angiotensin II antagonists, antidiuretic hormone agonists, antidiuretic hormone antagonists, bradykinin antagonists, CD4, ceredase, CSF's, enkephalins, F'AB fragments, IgE
peptide suppressors, IGF-1, neurotrophic factors, growth factors, parathyroid hormone and agonists, parathyroid hormone antagonists, prostaglandin antagonists, pentigetide, protein C, protein S, renin inhibitors, thymosin alpha-1, thrombolytics, TNF, vaccines, vasopressin antagonist analogs, alpha-1 antitrypsin (recombinant).
The prior art teach a variety of techniques suitable for controlling transderma7_ current generators. It should be understood electrically a~~sisted transdermal delivery of peptides and proteins a:~ well as the phenomenon of electroosmosis, have been disclo;aed in the prior art.
Examples of relevant art includes:
U.S. Patent 3,618,601 - tE:aches automatic control of an iontophoretic current source.
U.S. Patent 4,808,152 - te=aches an adjustable iontophoretic generator with programmable output.
U.S. Patent 4,141,359 - teaches a feedback controlled current source with automatic shutdown in the presence of excessive voltage buildup.
U.S. Patent 4,292,968 - teaches a an iontophoretic generator which operates in a constant current mode, but which may operate in a constant voltage mode if in the presence of high electrode impedance.
PCT.patent application WO 88/08729, teaches an iontophoretic drug delivery system which provides closed loop control of the driving current.
European patent application 0 309 093 EPA -teaches low frequency oscillator for the application of drugs. The device uses a waveform having rapid rise time and a slow fall off time.
U.S. Patent 4,725,263 - teaches a programmable constant current source for the transdermal application of drugs.
U.S. Patent 4,406,658 - teaches an iontophoretic device for the delivery of drugs. The circuitry includes a current control circuit which ramps the current values in accordance with a timer control circuit.
Summary of the Invention In contrast to this prior art, the present invention provides open loop feedback control of the rate of drug delivery as a function of a measurement of patient activity.
In particular, the present invention has particular utility in delivering drugs whose delivery rate is dependent upon the physical activity of a patient.
Specific examples of such drugs and the corresponding patient motion or activity include the following: delivery of theophylline or epinephrine for the treatment of apnea;
delivery of an antitussive such as dextromethorphan for the treatment of coughing; delivery of an anticonvulsant for the treatment of an epileptic seizure; delivery of insulin based upon the level of patient activity (e. g., lower insulin delivery rate for more vigorous levels of patient activity);
delivery of antiparkinson agent in response to patient shaking; delivery of antispasmodics such as diazepam for treatment of muscle spasms; and delivery of an antiemetic such as scopolamine or meclizine, in response to motion, for the treatment of motion sickness.
This object and others will become apparent from the following detailed description when read in conjunction with the accompanying drawings.
Brief Description of the Drawings In the drawings, like reference numerals indicate corresponding structure throughout t:he several views in which: FIG. 1 depicts a patient using the iontophoretic delivery system;
FIG. 2 is a functional block diagram showing the electronic portion of the invention; and FIG. 3 is an exploded view of the iontophoretic patch depicting structural relations>hips between the elements of the device.
Detailed Description of the Preferred Embodiment In the following description, reference is made to an illustrative embodiment for carrying out the invention.
It should be understood that other embodiments may be utilized without departing from the scope of the invention.
Some transdermally deliverable drugs should be administered at a rate which takes into account the underlying metabolic state or activity level of the recipient.
For example certain drugs are metabolized more rapidly during exercise. In these :instances, the therapeutic dose of the drug rises with increases in exercise. By way of contrast, other drugs such as pain relieving drugs may be required in smaller doses during exercise because the recipient may be distracted by physical exercise and the mental concentration associated with the activity. In these instances, the therapeutic dose of the drug may be lower with increased exercise. In general, charged drugs may be cationic or anionic in form. For these reasons the polarity of the electrode reservoirs must be adapted to the form of the drug.
Figure 1 shows-a patient l0 wearing the patch 12 on the chest. The iontophoretic transdermal drug delivery patch 12 includes drug reservoirs; a current generator, appropriate electrode areas and a suitablevactivity sensor.
The use of physical activity as a method of controlling a medical device is known from U.S. Patent 4,428,378 issued Jan. 31, 1984 to Anderson, et al.
A variety of activity sensors may be used to access the patient's physical activity level. However, it is preferred to use a piezoelectric sensor of the type taught by the Anderson reference. It should be appreciated that other forms of. activity sensing such as myoelectric sensing, may be used as well.
In operation, the physical activity of the patient is detected by the sensor which is responsive to the body motion proximate the treatment site. In response to the physical activity of the patient, the current supplied to the patch electrode is regulated, which in turn controls the rate of drug administration. In many instances the rate of drug delivery should increase with increasing physical activity. However, in some instances the rate of drug delivery should decrease with increasing activity. The illustrative embodiment increases drug delivery with increases in activity.
FIG. 2 is a functional block diagram showing the electronic portion of the invention. The electronic portion ~~ a ~ d~ ~° ~ ~'° '~ '~i of the invention is composed of several interconnected modules. An activity monitoring module 20 switches between a high and a low state with increasing frequency as activity increases. These level changes are applied to the trigger module 21. The trigger module contains a leading edge detector circuit to convert activity level changes to narrow trigger pulses. These trigger pulsea trigger the one shot module 22 which in turn generates fixed pulse width pulses of approximately 10 ms. The output of the one shot module is low pass filtered by filter module 23. The output of the averager 23 is compared to a reference signal in comparator module 24. The switching module 25 switches the output current source 28 in response to the activity level of the patient.
The circuitry shown operates at a lower basal delivery rate and a higher activity based delivery rate.
In the absence of patient. activity, the activity module generates essentially no activity counts. In this instance, the one shot module 22 out=put goes to a logic zero. After a brief delay related to the time constant of the averager module 23 the delivery rate drops to a minimum basal rate. In the presence of high patient activity the one shot operates at the activity based rate to establish a maximum drug delivery rate.
The activity module 20, includes a piezo sensor 27 which is coupled to the patient. This type of transducer deflects in response to patient activity. This sensor is coupled to an integrated circuit 26 which incorporates certain circuit functions more fully described in the incorporated reference. However, in general the activity sensor tracks the activity motion signal of the body, and generates an output which is linearly proportional to the excitation frequency supplied to the sensor by the body. It has been found that this type of activity signal correlates well with the oxygen consumption of the patient over a wide 6~~~:, ~
., t'~ ~ ..u range of activities. In operation the circuitry of module 20 generates activity counts which are supplied to trigger pulse generator 21.
The trigger pulse generator serves to buffer and square up the activity count pulses. It is preferred to use CMOS logic connected as a leading edge detector to perform this detection and trigger pulse stretching function.
The one shot module 22 receives the output of the trigger pulse generator. This trigger pulse generator 21 output signal is used as a triggering input to a triggerable one-shot multivibrator contained in one-shot module 22. The output of the one-shot is a fixed pulse width pulse. The output frequency of the one-shot module 22, tracks the triggering input frequency. In the absence of a trigger input the one-shot 22 output is at a logic zero state. As patient activity increases, pulses are supplied to an averager 23 at an increasing rate. The averager accumulates or integrates these pulses.
The function of the averager 23 is to prevent rapid excursions in the output current source 28 electrode drive circuit.
The comparator 24 compares the averaged output of the averager 23 with a reference value and toggles a switching circuit 25. Slight hysteresis is provided to ensure that rapid excursions of the current output do not take place.
The switching circuit 25 controls the output current source module 28. In operation, field effect transistor 29 operates in a constant current mode, sinking current from the 9 volt battery supply 30, through the reservoirs and electrodes. Field effect transistor 19 operates as a switch to shunt resistor 18 to increase the delivery rate to the higher activated determined value.
FIG. 3 is an exploded view of the iontophoretic "patch" depicting structural relationships between the q elements of the device. It is preferred to dispense the patch as a unitary, disposable, single use drug delivery system. However it should be apparent that certain modifications may be made to the device described to render it reusable.
In general, an adhesive is. used to mount the patch to the patient. This adhesive is attached to a conformal reservoir housing 41 on its under side 43. The separator 16 between the two reservoirs should have sufficient adhesive to isolate the two reservoirs 31, and 32 to prevent short circuiting of the patch. The upper surface 44 of the reservoir housing 41, may be adhesively attached to the flex circuit 36.
It is preferred to mount the various electronic components 37 on a flexible circuit board 36 to permit the patch to conform to patient contours.. It is preferred to mount the activity sensor 38 on the flexible circuit board as well, to permit deflection of the: circuit board to stress the piezo sensor. The deflection of the circuit board 36 communicates the patients physical motion to the sensor. A
foam circuit housing 35 may be used to locate and protect the batteries 33 and other high profile circuit components.
These electronic structures may be sealed by the use of a thin cover 34. The foam circuit housing 35 may be adhesively attached directly to the reservoir housing thus sealing the flex board within the patch.
A variety of drug delivery configurations are possible with the two reservoir patch.
In the preferred embodiment, a single gelled drug reservoir 32 is stored in a suitable: cavity 39. In this configuration the drug reservoir 32 is connected to one of the circuit electrodes 45. In a similar fashion a salt may be gelled with a suitable material t.o form the a gelled counter- reservoir 31 skin connection. This other tissue connection is located proximate to the drug delivery 2 1~°~ PCT/US91/02160 t~ a~~
k~
reservoir to establish the current path of the circuit. As shown in the figure, the two reservoirs have different surface areas. It may be preferred to use the larger area reservoir 31 as the negative interface to reduce skin irritation.
In operation., either cavity 39 or 42 may contain the drug reservoir, depending upon whether the drug is in cationic or anionic form. It is conventional to store such drugs in solid phase gels, ointment gels or in a fiber matrixes. Additionally, it may be desirable to simultaneously dispense two separate drugs with one patch system. For example, a cationic drug may be placed in the first cavity while the second cavity may contain an anionic drug.
The activity sensor may switch the polarity in response to increased activity, thereby delivering a first cationic drug at a basal activity level and a second cationic drug in response to increased activity levels.
Suitable switch reversal current sources are known from U.S.
Patent 4,406,658 which is incorporated by reference. This configuration may also be applied to two drugs in anionic form.
In use, the patch is activated by closing a suitable switch 17 which supplies current to the circuitry.
The mounting adhesive on surface 43 may be exposed by removing a suitable wrapper. At this point the patch is placed on the skin of the patient. The patch may be used on the upper torso or other area where activity based measurements of patient activity are most accurately transcribed. This conformal structure provide adequate coupling between the patient and the sensor 27 to achieve this property.
Background of the Invention Field of the Invention The present invention relates to transdermal electrotransport drug administration devices and, more particularly, to a patch system which includes a current generator and a sensor for feedback control of the patients activity level to regulate the rate of drug delivery.
Description of the Prior Art Transdermal elctrotransport is a method of applying a medication to a patient l~hrough the application of an electromotive force to drive chemicals through the skin. The iontophoretic application of medicaments avoids many problems associated with the p~=_rcutaneous delivery of drugs. Experimentation has been directed to, development of drugs Jultable for electrot~an~pert and, to patch electrode systems suitable for dispensing those drugs.
In general, there are two major mechanisms for electrotransport. Iontophoresis refers to the transport of charged substances, which electroso:mosis refers to the transdermal flux of a liquid solvent (e. g., the liquid solvent containing the uncharged drug or agent) which is induced by the presence of an electric field imposed across the skin by the donor electrode. As used herein the terms "iontophoresis" and "iontoppheroetic" refer to either, the delivery of charged drugs or agents, the delivery of uncharged drugs or agents by the process of electroosmosis, or both.
The expressions "drug" and "therapeutic agent" are used interchangeably and are intended to have their broadest «~
interpretation as any therapeutically active substance which is delivered to a living organism to produce a desired, usually beneficial, effect. In general, this includes therapeutic agents in all of the major therapeutic areas including, but not limited to, anti-infectives such as antibiotics and antiviral agents, analgesics and analgesic combinations, anesthetics, anorexics, antiarthritics, antiasthmatic agents, anticonvulsants, antidepressants, antidiabetic agents, antidiarrheals, antihistamines, anti-inflammatory agents, antimigraine preparations, antimotion sickness preparations, antinauseants, antineoplastics, antiparkinsonism drugs, antipruritics, antipsychotics, antipyretics, antispasmodics, including gastrointestinal and urinary, anticholinergics, sympathomimetrics, xanthine derivatives, cardiovascular preparations including calcium channel blockers, beta-blockers, antiarrythmics, antihypertensives, diuretics, vasodilators, including general, coronary, peripheral and cerebral, central nervous system stimulants, cough and cold preparations, decongestants, diagnostics, hormones, hypnotics, immunosuppressives, muscle relaxants, parasympatholytics, parasympathomimetrics, proteins, peptides, psychostimulants, sedatives and tranquilizers.
The invention is also useful in the controlled delivery or peptides, polypeptides, proteins and other macromolecules. These macromolecular substances typically have a molecular weight of at least about 300 daltons, and more typically a molecular weight in the range of about 300 to 40,000 daltons. Specific examples of peptides and proteins in this size range include, without limitation, LHRH, LHRH analogs such as buserelin, gonadorelin, naphrelin and leuprolide, GHRH, insulin, heparin, calcitonin, endorphin, TRH, NT-36 (chemical name: N=[((s)-4oxo-2-azetidinyl]carbonyl]-L-hystidyl-L-prolinamide), liprecin, pituitary hormones (e. g., HGH, HMG, HCG, desmopressin ' aF , ''1 r ~~~ ~~~1~ 1 acetate, etc.), follicle luteoids, aANF, growth factor releasing factor (GFRF), QMSH, somatostatin, bradykinin, somatotropin, platelet-derived growth factor, asparaginase, bleomycin sulfate, chymopapain, cholecystokinin, chorionic gonadotropin, corticotropin (ACTH), erythropoietin, epoprostenol (platelet aggregation inhibitor), glucagon, hyaluronidase, interferon, interleuk.in-1, interleukin-2 menotropins (urofollitropin (FSH) and LH), oxytocin, streptokinase, tissue plasminogen activator, urokinase, vasopressin, ACTH analogs, ANP, ANP clearance inhibitors, angiotensin II antagonists, antidiuretic hormone agonists, antidiuretic hormone antagonists, bradykinin antagonists, CD4, ceredase, CSF's, enkephalins, F'AB fragments, IgE
peptide suppressors, IGF-1, neurotrophic factors, growth factors, parathyroid hormone and agonists, parathyroid hormone antagonists, prostaglandin antagonists, pentigetide, protein C, protein S, renin inhibitors, thymosin alpha-1, thrombolytics, TNF, vaccines, vasopressin antagonist analogs, alpha-1 antitrypsin (recombinant).
The prior art teach a variety of techniques suitable for controlling transderma7_ current generators. It should be understood electrically a~~sisted transdermal delivery of peptides and proteins a:~ well as the phenomenon of electroosmosis, have been disclo;aed in the prior art.
Examples of relevant art includes:
U.S. Patent 3,618,601 - tE:aches automatic control of an iontophoretic current source.
U.S. Patent 4,808,152 - te=aches an adjustable iontophoretic generator with programmable output.
U.S. Patent 4,141,359 - teaches a feedback controlled current source with automatic shutdown in the presence of excessive voltage buildup.
U.S. Patent 4,292,968 - teaches a an iontophoretic generator which operates in a constant current mode, but which may operate in a constant voltage mode if in the presence of high electrode impedance.
PCT.patent application WO 88/08729, teaches an iontophoretic drug delivery system which provides closed loop control of the driving current.
European patent application 0 309 093 EPA -teaches low frequency oscillator for the application of drugs. The device uses a waveform having rapid rise time and a slow fall off time.
U.S. Patent 4,725,263 - teaches a programmable constant current source for the transdermal application of drugs.
U.S. Patent 4,406,658 - teaches an iontophoretic device for the delivery of drugs. The circuitry includes a current control circuit which ramps the current values in accordance with a timer control circuit.
Summary of the Invention In contrast to this prior art, the present invention provides open loop feedback control of the rate of drug delivery as a function of a measurement of patient activity.
In particular, the present invention has particular utility in delivering drugs whose delivery rate is dependent upon the physical activity of a patient.
Specific examples of such drugs and the corresponding patient motion or activity include the following: delivery of theophylline or epinephrine for the treatment of apnea;
delivery of an antitussive such as dextromethorphan for the treatment of coughing; delivery of an anticonvulsant for the treatment of an epileptic seizure; delivery of insulin based upon the level of patient activity (e. g., lower insulin delivery rate for more vigorous levels of patient activity);
delivery of antiparkinson agent in response to patient shaking; delivery of antispasmodics such as diazepam for treatment of muscle spasms; and delivery of an antiemetic such as scopolamine or meclizine, in response to motion, for the treatment of motion sickness.
This object and others will become apparent from the following detailed description when read in conjunction with the accompanying drawings.
Brief Description of the Drawings In the drawings, like reference numerals indicate corresponding structure throughout t:he several views in which: FIG. 1 depicts a patient using the iontophoretic delivery system;
FIG. 2 is a functional block diagram showing the electronic portion of the invention; and FIG. 3 is an exploded view of the iontophoretic patch depicting structural relations>hips between the elements of the device.
Detailed Description of the Preferred Embodiment In the following description, reference is made to an illustrative embodiment for carrying out the invention.
It should be understood that other embodiments may be utilized without departing from the scope of the invention.
Some transdermally deliverable drugs should be administered at a rate which takes into account the underlying metabolic state or activity level of the recipient.
For example certain drugs are metabolized more rapidly during exercise. In these :instances, the therapeutic dose of the drug rises with increases in exercise. By way of contrast, other drugs such as pain relieving drugs may be required in smaller doses during exercise because the recipient may be distracted by physical exercise and the mental concentration associated with the activity. In these instances, the therapeutic dose of the drug may be lower with increased exercise. In general, charged drugs may be cationic or anionic in form. For these reasons the polarity of the electrode reservoirs must be adapted to the form of the drug.
Figure 1 shows-a patient l0 wearing the patch 12 on the chest. The iontophoretic transdermal drug delivery patch 12 includes drug reservoirs; a current generator, appropriate electrode areas and a suitablevactivity sensor.
The use of physical activity as a method of controlling a medical device is known from U.S. Patent 4,428,378 issued Jan. 31, 1984 to Anderson, et al.
A variety of activity sensors may be used to access the patient's physical activity level. However, it is preferred to use a piezoelectric sensor of the type taught by the Anderson reference. It should be appreciated that other forms of. activity sensing such as myoelectric sensing, may be used as well.
In operation, the physical activity of the patient is detected by the sensor which is responsive to the body motion proximate the treatment site. In response to the physical activity of the patient, the current supplied to the patch electrode is regulated, which in turn controls the rate of drug administration. In many instances the rate of drug delivery should increase with increasing physical activity. However, in some instances the rate of drug delivery should decrease with increasing activity. The illustrative embodiment increases drug delivery with increases in activity.
FIG. 2 is a functional block diagram showing the electronic portion of the invention. The electronic portion ~~ a ~ d~ ~° ~ ~'° '~ '~i of the invention is composed of several interconnected modules. An activity monitoring module 20 switches between a high and a low state with increasing frequency as activity increases. These level changes are applied to the trigger module 21. The trigger module contains a leading edge detector circuit to convert activity level changes to narrow trigger pulses. These trigger pulsea trigger the one shot module 22 which in turn generates fixed pulse width pulses of approximately 10 ms. The output of the one shot module is low pass filtered by filter module 23. The output of the averager 23 is compared to a reference signal in comparator module 24. The switching module 25 switches the output current source 28 in response to the activity level of the patient.
The circuitry shown operates at a lower basal delivery rate and a higher activity based delivery rate.
In the absence of patient. activity, the activity module generates essentially no activity counts. In this instance, the one shot module 22 out=put goes to a logic zero. After a brief delay related to the time constant of the averager module 23 the delivery rate drops to a minimum basal rate. In the presence of high patient activity the one shot operates at the activity based rate to establish a maximum drug delivery rate.
The activity module 20, includes a piezo sensor 27 which is coupled to the patient. This type of transducer deflects in response to patient activity. This sensor is coupled to an integrated circuit 26 which incorporates certain circuit functions more fully described in the incorporated reference. However, in general the activity sensor tracks the activity motion signal of the body, and generates an output which is linearly proportional to the excitation frequency supplied to the sensor by the body. It has been found that this type of activity signal correlates well with the oxygen consumption of the patient over a wide 6~~~:, ~
., t'~ ~ ..u range of activities. In operation the circuitry of module 20 generates activity counts which are supplied to trigger pulse generator 21.
The trigger pulse generator serves to buffer and square up the activity count pulses. It is preferred to use CMOS logic connected as a leading edge detector to perform this detection and trigger pulse stretching function.
The one shot module 22 receives the output of the trigger pulse generator. This trigger pulse generator 21 output signal is used as a triggering input to a triggerable one-shot multivibrator contained in one-shot module 22. The output of the one-shot is a fixed pulse width pulse. The output frequency of the one-shot module 22, tracks the triggering input frequency. In the absence of a trigger input the one-shot 22 output is at a logic zero state. As patient activity increases, pulses are supplied to an averager 23 at an increasing rate. The averager accumulates or integrates these pulses.
The function of the averager 23 is to prevent rapid excursions in the output current source 28 electrode drive circuit.
The comparator 24 compares the averaged output of the averager 23 with a reference value and toggles a switching circuit 25. Slight hysteresis is provided to ensure that rapid excursions of the current output do not take place.
The switching circuit 25 controls the output current source module 28. In operation, field effect transistor 29 operates in a constant current mode, sinking current from the 9 volt battery supply 30, through the reservoirs and electrodes. Field effect transistor 19 operates as a switch to shunt resistor 18 to increase the delivery rate to the higher activated determined value.
FIG. 3 is an exploded view of the iontophoretic "patch" depicting structural relationships between the q elements of the device. It is preferred to dispense the patch as a unitary, disposable, single use drug delivery system. However it should be apparent that certain modifications may be made to the device described to render it reusable.
In general, an adhesive is. used to mount the patch to the patient. This adhesive is attached to a conformal reservoir housing 41 on its under side 43. The separator 16 between the two reservoirs should have sufficient adhesive to isolate the two reservoirs 31, and 32 to prevent short circuiting of the patch. The upper surface 44 of the reservoir housing 41, may be adhesively attached to the flex circuit 36.
It is preferred to mount the various electronic components 37 on a flexible circuit board 36 to permit the patch to conform to patient contours.. It is preferred to mount the activity sensor 38 on the flexible circuit board as well, to permit deflection of the: circuit board to stress the piezo sensor. The deflection of the circuit board 36 communicates the patients physical motion to the sensor. A
foam circuit housing 35 may be used to locate and protect the batteries 33 and other high profile circuit components.
These electronic structures may be sealed by the use of a thin cover 34. The foam circuit housing 35 may be adhesively attached directly to the reservoir housing thus sealing the flex board within the patch.
A variety of drug delivery configurations are possible with the two reservoir patch.
In the preferred embodiment, a single gelled drug reservoir 32 is stored in a suitable: cavity 39. In this configuration the drug reservoir 32 is connected to one of the circuit electrodes 45. In a similar fashion a salt may be gelled with a suitable material t.o form the a gelled counter- reservoir 31 skin connection. This other tissue connection is located proximate to the drug delivery 2 1~°~ PCT/US91/02160 t~ a~~
k~
reservoir to establish the current path of the circuit. As shown in the figure, the two reservoirs have different surface areas. It may be preferred to use the larger area reservoir 31 as the negative interface to reduce skin irritation.
In operation., either cavity 39 or 42 may contain the drug reservoir, depending upon whether the drug is in cationic or anionic form. It is conventional to store such drugs in solid phase gels, ointment gels or in a fiber matrixes. Additionally, it may be desirable to simultaneously dispense two separate drugs with one patch system. For example, a cationic drug may be placed in the first cavity while the second cavity may contain an anionic drug.
The activity sensor may switch the polarity in response to increased activity, thereby delivering a first cationic drug at a basal activity level and a second cationic drug in response to increased activity levels.
Suitable switch reversal current sources are known from U.S.
Patent 4,406,658 which is incorporated by reference. This configuration may also be applied to two drugs in anionic form.
In use, the patch is activated by closing a suitable switch 17 which supplies current to the circuitry.
The mounting adhesive on surface 43 may be exposed by removing a suitable wrapper. At this point the patch is placed on the skin of the patient. The patch may be used on the upper torso or other area where activity based measurements of patient activity are most accurately transcribed. This conformal structure provide adequate coupling between the patient and the sensor 27 to achieve this property.
Claims (14)
1. Apparatus for the iontophoretic delivery of drugs to a patient comprising:
a first reservoir containing a charged ionic substance for delivery to said patient;
a second reservoir containing a charged ionic substance proximate said first reservoir;
current generator means coupled to said first and second reservoirs for supplying current to said electrodes in response to a control signal;
activity sensor means for monitoring the physical activity of said patient and for generating an activity signal indicative of said activity;
control means coupled to said activity monitoring means and to said current generator means responsive to said activity signal for generating a control signal for controlling said current generator means as a function of said activity signal.
a first reservoir containing a charged ionic substance for delivery to said patient;
a second reservoir containing a charged ionic substance proximate said first reservoir;
current generator means coupled to said first and second reservoirs for supplying current to said electrodes in response to a control signal;
activity sensor means for monitoring the physical activity of said patient and for generating an activity signal indicative of said activity;
control means coupled to said activity monitoring means and to said current generator means responsive to said activity signal for generating a control signal for controlling said current generator means as a function of said activity signal.
2. The apparatus of claim 1 wherein said current generator operates at a preset minimum current level in the presence of patient activity below a predetermined minimum.
3. The apparatus of claim 1 wherein said current generator operates at a preset maximum current level in the presence of patient activity above a predetermined minimum.
4. Unitary iontophoretic drug delivery apparatus for transdermal delivery of a material to a patients body comprising:
a conformal carrier, including a reservoir means for storing gelled ionic substances;
a flexible circuit package containing activity monitoring circuitry and current delivery circuitry, coupled to said reservoir means;
whereby motion of said patient activates said activity monitoring circuitry.
a conformal carrier, including a reservoir means for storing gelled ionic substances;
a flexible circuit package containing activity monitoring circuitry and current delivery circuitry, coupled to said reservoir means;
whereby motion of said patient activates said activity monitoring circuitry.
5. An iontophoretic drug delivery system for delivering two drugs to a patient comprising:
a first cationic drug reservoir;
a second anionic drug reservoir;
current generator means coupled to said first and second reservoirs for supplying current to said reservoirs in response to a control signal;
activity sensor means for monitoring the physical activity of said patient and for generating an activity signal indicative of said activity;
control means coupled to said activity monitoring means and to said current generator means responsive to said activity signal for generating a control signal for controlling said current generator means as a function of said activity signal.
a first cationic drug reservoir;
a second anionic drug reservoir;
current generator means coupled to said first and second reservoirs for supplying current to said reservoirs in response to a control signal;
activity sensor means for monitoring the physical activity of said patient and for generating an activity signal indicative of said activity;
control means coupled to said activity monitoring means and to said current generator means responsive to said activity signal for generating a control signal for controlling said current generator means as a function of said activity signal.
6. An iontophoretic drug delivery system for delivering two drugs to a patient comprising:
a first cationic drug reservoir;
a second cationic drug reservoir;
current generator means coupled to said first and second reservoirs for supplying current to said reservoirs in a first polarity in response to a first control signal and for supplying current to said reservoirs in a second polarity in response to a second control signal;
activity sensor means for monitoring the physical activity of said patient and for generating an activity signal indicative of said activity;
control means coupled to said activity monitoring means and to said current generator means responsive to said activity signal for generating a first control signal in the presence of low activity and for generating a second control signal in the presence of higher activity above a predetermined threshold.
a first cationic drug reservoir;
a second cationic drug reservoir;
current generator means coupled to said first and second reservoirs for supplying current to said reservoirs in a first polarity in response to a first control signal and for supplying current to said reservoirs in a second polarity in response to a second control signal;
activity sensor means for monitoring the physical activity of said patient and for generating an activity signal indicative of said activity;
control means coupled to said activity monitoring means and to said current generator means responsive to said activity signal for generating a first control signal in the presence of low activity and for generating a second control signal in the presence of higher activity above a predetermined threshold.
7. An iontophoretic drug delivery system for delivering two drugs to a patient comprising:
a first anionic drug reservoir;
a second antionic drug reservoir;
current generator means coupled to said first and second reservoirs for supplying current to said reservoirs in a first polarity in response to a first control signal and for supplying current to said reservoirs in a second polarity in response to a second control signal;
activity sensor means for monitoring the physical activity of said patient and for generating an activity signal indicative of said activity;
control means coupled to said activity monitoring means and to said current generator means responsive to said activity signal for generating a first control signal in the presence of low activity and for generating a second control signal in the presence of higher activity above a predetermined threshold.
a first anionic drug reservoir;
a second antionic drug reservoir;
current generator means coupled to said first and second reservoirs for supplying current to said reservoirs in a first polarity in response to a first control signal and for supplying current to said reservoirs in a second polarity in response to a second control signal;
activity sensor means for monitoring the physical activity of said patient and for generating an activity signal indicative of said activity;
control means coupled to said activity monitoring means and to said current generator means responsive to said activity signal for generating a first control signal in the presence of low activity and for generating a second control signal in the presence of higher activity above a predetermined threshold.
8. Apparatus for the transdermal electrotransport of drugs to a patient comprising:
a first reservoir containing a charged ionic substance for delivery to said patient;
a second reservoir containing a charged ionic substance proximate said first reservoir;
current generator means coupled to said first and second reservoirs for supplying current to said electrodes in response to a control signal;
activity sensor means for monitoring the physical activity of said patient and for generating an activity signal indicative of said activity;
control means coupled to said activity monitoring means and to said current generator means responsive to said activity signal for generating a control signal for controlling said current generator means as a function of said activity signal.
a first reservoir containing a charged ionic substance for delivery to said patient;
a second reservoir containing a charged ionic substance proximate said first reservoir;
current generator means coupled to said first and second reservoirs for supplying current to said electrodes in response to a control signal;
activity sensor means for monitoring the physical activity of said patient and for generating an activity signal indicative of said activity;
control means coupled to said activity monitoring means and to said current generator means responsive to said activity signal for generating a control signal for controlling said current generator means as a function of said activity signal.
9. The apparatus of claim 1 wherein said current generator operates at a preset minimum current level in the presence of patient activity below a predetermined minimum.
10. The apparatus of claim 1 wherein said current generator operates at a preset maximum current level in the presence of patient activity above a predetermined minimum.
11. Unitary electrotransport drug delivery apparatus for transdermal delivery of a material to a patients body comprising:
a conformal carrier, including a reservoir means for storing gelled ionic substances;
a flexible circuit package containing activity monitoring circuitry and current delivery circuitry, coupled to said reservoir means;
whereby motion of said patient activates said activity monitoring circuitry.
a conformal carrier, including a reservoir means for storing gelled ionic substances;
a flexible circuit package containing activity monitoring circuitry and current delivery circuitry, coupled to said reservoir means;
whereby motion of said patient activates said activity monitoring circuitry.
12. An electrotransport drug delivery system for delivering two drugs to a patient comprising:
a first cationic drug reservoir;
a second anionic drug reservoir;
current generator means coupled to said first and second reservoirs for supplying current to said reservoirs in response to a control signal;
activity sensor means for monitoring the physical activity of said patient and for generating an activity signal indicative of said activity;
control means coupled to said activity monitoring means and to said current generator means responsive to said activity signal for generating a control signal for controlling said current generator means as a function of said activity signal.
a first cationic drug reservoir;
a second anionic drug reservoir;
current generator means coupled to said first and second reservoirs for supplying current to said reservoirs in response to a control signal;
activity sensor means for monitoring the physical activity of said patient and for generating an activity signal indicative of said activity;
control means coupled to said activity monitoring means and to said current generator means responsive to said activity signal for generating a control signal for controlling said current generator means as a function of said activity signal.
13. An electrotransport drug delivery system for delivering two drugs to a patient comprising:
a first cationic drug reservoir;
a second cationic drug reservoir;
current generator means coupled to said first and second reservoirs for supplying current to said reservoirs in a first polarity in response to a first control signal and for supplying current to said reservoirs in a second polarity in response to a second control signal;
activity sensor means for monitoring the physical activity of said patient and for generating an activity signal indicative of said activity;
control means coupled to said activity monitoring means and to said current generator means responsive to said activity signal for generating a first control signal in the presence of low activity and for generating a second control signal in the presence of higher activity above a predetermined threshold.
a first cationic drug reservoir;
a second cationic drug reservoir;
current generator means coupled to said first and second reservoirs for supplying current to said reservoirs in a first polarity in response to a first control signal and for supplying current to said reservoirs in a second polarity in response to a second control signal;
activity sensor means for monitoring the physical activity of said patient and for generating an activity signal indicative of said activity;
control means coupled to said activity monitoring means and to said current generator means responsive to said activity signal for generating a first control signal in the presence of low activity and for generating a second control signal in the presence of higher activity above a predetermined threshold.
14. An electrotransport drug delivery system for delivering two drugs to a patient comprising:
a first anionic drug reservoir;
a second antionic drug reservoir;
current generator means coupled to said first and second reservoirs for supplying current to said reservoirs in a first polarity in response to a first control signal and for supplying current to said reservoirs in a second polarity in response to a second control signal;
activity sensor means for monitoring the physical activity of said patient and for generating an activity signal indicative of said activity;
control means coupled to said activity monitoring means and to said current generator means responsive to said activity signal for generating a first control signal in the presence of low activity and for generating a second control signal in the presence of higher activity above a predetermined threshold.
a first anionic drug reservoir;
a second antionic drug reservoir;
current generator means coupled to said first and second reservoirs for supplying current to said reservoirs in a first polarity in response to a first control signal and for supplying current to said reservoirs in a second polarity in response to a second control signal;
activity sensor means for monitoring the physical activity of said patient and for generating an activity signal indicative of said activity;
control means coupled to said activity monitoring means and to said current generator means responsive to said activity signal for generating a first control signal in the presence of low activity and for generating a second control signal in the presence of higher activity above a predetermined threshold.
Applications Claiming Priority (5)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US50242290A | 1990-03-30 | 1990-03-30 | |
US07/671,267 US5213568A (en) | 1990-03-30 | 1991-03-18 | Activity controlled electrotransport drug delivery device |
US671,267 | 1991-03-18 | ||
US502,422 | 1991-03-18 | ||
PCT/US1991/002160 WO1991015261A1 (en) | 1990-03-30 | 1991-03-29 | Activity controlled electrotransport drug delivery device |
Publications (2)
Publication Number | Publication Date |
---|---|
CA2079007A1 CA2079007A1 (en) | 1991-10-01 |
CA2079007C true CA2079007C (en) | 2001-08-07 |
Family
ID=27054150
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CA002079007A Expired - Lifetime CA2079007C (en) | 1990-03-30 | 1991-03-29 | Activity controlled electrotransport drug delivery device |
Country Status (8)
Country | Link |
---|---|
US (1) | US5213568A (en) |
EP (1) | EP0522062B1 (en) |
JP (1) | JP3300953B2 (en) |
AT (1) | ATE142116T1 (en) |
AU (1) | AU649439B2 (en) |
CA (1) | CA2079007C (en) |
DE (1) | DE69121885T2 (en) |
FI (1) | FI111131B (en) |
Cited By (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US20210212631A1 (en) * | 2011-01-10 | 2021-07-15 | Bodiguide Inc. | System and method for patient monitoring |
Families Citing this family (102)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5499967A (en) * | 1992-02-27 | 1996-03-19 | Societe Anonyme Dite: Laboratoires D'hygiene Societe Anonyme Dite: Et De Dietetique (L.H.D.) | Transdermal drug delivery device with waveshape generator |
US5427585A (en) * | 1993-03-29 | 1995-06-27 | Bettinger; David S. | On-demand iontophoretic system |
US5508030A (en) * | 1993-08-05 | 1996-04-16 | Bierman; Howard R. | Creating new capillary blood pools for practicing bidirectional medicine |
US5635204A (en) * | 1994-03-04 | 1997-06-03 | Montefiore Medical Center | Method for transdermal induction of anesthesia, analgesia or sedation |
US7027859B1 (en) | 1994-09-26 | 2006-04-11 | Alza Corporation | Electrotransport delivery device having improved safety and reduced abuse potential |
IE960312A1 (en) * | 1995-06-02 | 1996-12-11 | Alza Corp | An electrotransport delivery device with voltage boosting¹circuit |
SE9601528D0 (en) | 1996-04-23 | 1996-04-23 | Pharmacia Ab | Transdermally administered dextromethorphan as an antitissue agent |
US6047208A (en) * | 1997-08-27 | 2000-04-04 | Becton, Dickinson And Company | Iontophoretic controller |
CA2308489A1 (en) | 1997-10-09 | 1999-04-22 | Emory University | Method and devices for transdermal delivery of lithium |
KR20010033208A (en) | 1997-12-16 | 2001-04-25 | 스톤 스티븐 에프. | Regulator with artificial load to maintain regulated delivery |
ATE354400T1 (en) | 1997-12-17 | 2007-03-15 | Alza Corp | IONTOPHORETIC DEVICE WITH PROGRAMMABLE ELECTRICAL CURRENT ADJUSTMENT |
US6128520A (en) * | 1998-08-06 | 2000-10-03 | Medtronic, Inc. | Ambulatory recorder having volatile and non-volatile memories |
US6077223A (en) * | 1998-08-06 | 2000-06-20 | Medtronic, Inc. | Ambulatory recorder having control screen to present dual interface for dual users |
US6119029A (en) * | 1998-08-06 | 2000-09-12 | Medtronic, Inc. | Ambulatory recorder having splash resistant sensor ports |
US6142938A (en) * | 1998-08-06 | 2000-11-07 | Medtronic Inc. | Ambulatory data recorder having ergonomically shaped housing |
US6141574A (en) * | 1998-08-06 | 2000-10-31 | Medtronic, Inc. | Ambulatory recorder having sliding period switches |
US6200264B1 (en) | 1998-08-06 | 2001-03-13 | Medtronic Inc. | Ambulatory recorder having wireless data transfer with a multi-plane lens |
US6014578A (en) * | 1998-08-06 | 2000-01-11 | Meotronic, Inc. | Ambulatory recorder having method of configuring size of data subject to loss in volatile memory |
US6115622A (en) * | 1998-08-06 | 2000-09-05 | Medtronic, Inc. | Ambulatory recorder having enhanced sampling technique |
US6154668A (en) * | 1998-08-06 | 2000-11-28 | Medtronics Inc. | Ambulatory recorder having a real time and non-real time processors |
US6532386B2 (en) | 1998-08-31 | 2003-03-11 | Johnson & Johnson Consumer Companies, Inc. | Electrotransort device comprising blades |
US6245013B1 (en) | 1998-12-14 | 2001-06-12 | Medtronic, Inc. | Ambulatory recorder having synchronized communication between two processors |
EP1171195B1 (en) * | 1999-04-16 | 2005-03-16 | Johnson & Johnson Consumer Companies, Inc. | Electrotransport delivery system comprising internal sensors |
US6516749B1 (en) * | 1999-06-18 | 2003-02-11 | Salasoft, Inc. | Apparatus for the delivery to an animal of a beneficial agent |
AU6076200A (en) | 1999-07-08 | 2001-01-30 | Johnson & Johnson Consumer Companies, Inc. | Exothermic bandage |
US6890553B1 (en) | 1999-07-08 | 2005-05-10 | Johnson & Johnson Consumer Companies, Inc. | Exothermic topical delivery device |
US7113821B1 (en) | 1999-08-25 | 2006-09-26 | Johnson & Johnson Consumer Companies, Inc. | Tissue electroperforation for enhanced drug delivery |
US7133717B2 (en) * | 1999-08-25 | 2006-11-07 | Johnson & Johnson Consumer Companies, Inc. | Tissue electroperforation for enhanced drug delivery and diagnostic sampling |
US6512950B2 (en) | 2000-02-18 | 2003-01-28 | University Of Utah Research Foundation | Methods for delivering agents using alternating current |
WO2001060448A1 (en) | 2000-02-18 | 2001-08-23 | University Of Utah Research Foundation | Methods for extracting substances using alternating current |
US7404815B2 (en) * | 2000-05-01 | 2008-07-29 | Lifescan, Inc. | Tissue ablation by shear force for sampling biological fluids and delivering active agents |
US7137975B2 (en) * | 2001-02-13 | 2006-11-21 | Aciont, Inc. | Method for increasing the battery life of an alternating current iontophoresis device using a barrier-modifying agent |
ATE419897T1 (en) * | 2001-10-24 | 2009-01-15 | Power Paper Ltd | DEVICE FOR THE CONTROLLED DELIVERY OF AN ACTIVE SUBSTANCE INTO THE SKIN |
US6638241B2 (en) * | 2002-01-03 | 2003-10-28 | Israel Yerushalmy | Apparatus for treating bruxism |
US10173008B2 (en) | 2002-01-29 | 2019-01-08 | Baxter International Inc. | System and method for communicating with a dialysis machine through a network |
US8775196B2 (en) | 2002-01-29 | 2014-07-08 | Baxter International Inc. | System and method for notification and escalation of medical data |
US8234128B2 (en) | 2002-04-30 | 2012-07-31 | Baxter International, Inc. | System and method for verifying medical device operational parameters |
US7596407B2 (en) | 2004-03-26 | 2009-09-29 | Solvay Pharmaceuticals, B.V. | Transdermal iontophoretic delivery of piperazinyl-2(3H)-benzoxazolone compounds |
EP1595542A1 (en) * | 2004-03-26 | 2005-11-16 | Solvay Pharmaceuticals B.V. | Transdermal iontophoretic delivery of piperazinyl-2(3H)-benzoxazolone compounds |
US7519409B2 (en) * | 2005-12-29 | 2009-04-14 | Medtronic, Inc. | Implantable cell/tissue-based biosensing device |
WO2007106557A2 (en) | 2006-03-14 | 2007-09-20 | University Of Southern California | Mems device for delivery of therapeutic agents |
EP2037999B1 (en) | 2006-07-07 | 2016-12-28 | Proteus Digital Health, Inc. | Smart parenteral administration system |
US8622991B2 (en) * | 2007-03-19 | 2014-01-07 | Insuline Medical Ltd. | Method and device for drug delivery |
US9220837B2 (en) | 2007-03-19 | 2015-12-29 | Insuline Medical Ltd. | Method and device for drug delivery |
MX2009010000A (en) | 2007-03-19 | 2010-03-17 | Insuline Medical Ltd | Drug delivery device. |
JP5243548B2 (en) | 2007-10-25 | 2013-07-24 | プロテウス デジタル ヘルス, インコーポレイテッド | Fluid communication port for information systems |
US8419638B2 (en) | 2007-11-19 | 2013-04-16 | Proteus Digital Health, Inc. | Body-associated fluid transport structure evaluation devices |
US8409133B2 (en) | 2007-12-18 | 2013-04-02 | Insuline Medical Ltd. | Drug delivery device with sensor for closed-loop operation |
JP5542691B2 (en) | 2007-12-20 | 2014-07-09 | ユニバーシティ オブ サザン カリフォルニア | Devices and methods for delivering therapeutic agents |
US20110160640A1 (en) * | 2008-01-18 | 2011-06-30 | Yanaki Jamal S | Operation management of active transdermal medicament patch |
US8862223B2 (en) * | 2008-01-18 | 2014-10-14 | Activatek, Inc. | Active transdermal medicament patch and circuit board for same |
US8337404B2 (en) | 2010-10-01 | 2012-12-25 | Flint Hills Scientific, Llc | Detecting, quantifying, and/or classifying seizures using multimodal data |
US8382667B2 (en) | 2010-10-01 | 2013-02-26 | Flint Hills Scientific, Llc | Detecting, quantifying, and/or classifying seizures using multimodal data |
US8571643B2 (en) | 2010-09-16 | 2013-10-29 | Flint Hills Scientific, Llc | Detecting or validating a detection of a state change from a template of heart rate derivative shape or heart beat wave complex |
CN102202708B (en) | 2008-05-08 | 2015-01-21 | 迷你泵有限责任公司 | Drug-delivery pumps and methods of manufacture |
US9333297B2 (en) | 2008-05-08 | 2016-05-10 | Minipumps, Llc | Drug-delivery pump with intelligent control |
EP2320989B1 (en) | 2008-05-08 | 2015-03-11 | MiniPumps, LLC | Implantable pumps and cannulas therefor |
US10089443B2 (en) | 2012-05-15 | 2018-10-02 | Baxter International Inc. | Home medical device systems and methods for therapy prescription and tracking, servicing and inventory |
US8057679B2 (en) | 2008-07-09 | 2011-11-15 | Baxter International Inc. | Dialysis system having trending and alert generation |
US8554579B2 (en) | 2008-10-13 | 2013-10-08 | Fht, Inc. | Management, reporting and benchmarking of medication preparation |
US8961458B2 (en) | 2008-11-07 | 2015-02-24 | Insuline Medical Ltd. | Device and method for drug delivery |
US20110105952A1 (en) * | 2009-10-30 | 2011-05-05 | Seventh Sense Biosystems, Inc. | Relatively small devices applied to the skin, modular systems, and methods of use thereof |
US20120277629A1 (en) | 2011-04-29 | 2012-11-01 | Seventh Sense Biosystems, Inc. | Systems and methods for collection and/or manipulation of blood spots or other bodily fluids |
WO2010101620A2 (en) | 2009-03-02 | 2010-09-10 | Seventh Sense Biosystems, Inc. | Systems and methods for creating and using suction blisters or other pooled regions of fluid within the skin |
WO2012018486A2 (en) | 2010-07-26 | 2012-02-09 | Seventh Sense Biosystems, Inc. | Rapid delivery and/or receiving of fluids |
AU2010284216B2 (en) | 2009-08-18 | 2015-10-15 | Minipumps, Llc | Electrolytic drug-delivery pump with adaptive control |
MX2012002762A (en) * | 2009-09-04 | 2012-06-12 | Minipumps Llc | Adhesive skin patch with pump for subcutaneous drug delivery. |
EP2493537B1 (en) * | 2009-10-30 | 2017-12-06 | Seventh Sense Biosystems, Inc. | Systems and methods for treating, sanitizing, and/or shielding the skin or devices applied to the skin |
WO2011094573A1 (en) | 2010-01-28 | 2011-08-04 | Seventh Sense Biosystems, Inc. | Monitoring or feedback systems and methods |
JP5841951B2 (en) | 2010-02-01 | 2016-01-13 | プロテウス デジタル ヘルス, インコーポレイテッド | Data collection system |
SG189763A1 (en) | 2010-02-01 | 2013-05-31 | Proteus Digital Health Inc | Two-wrist data gathering system |
US8562536B2 (en) | 2010-04-29 | 2013-10-22 | Flint Hills Scientific, Llc | Algorithm for detecting a seizure from cardiac data |
US8831732B2 (en) | 2010-04-29 | 2014-09-09 | Cyberonics, Inc. | Method, apparatus and system for validating and quantifying cardiac beat data quality |
US8649871B2 (en) | 2010-04-29 | 2014-02-11 | Cyberonics, Inc. | Validity test adaptive constraint modification for cardiac data used for detection of state changes |
WO2011163347A2 (en) | 2010-06-23 | 2011-12-29 | Seventh Sense Biosystems, Inc. | Sampling devices and methods involving relatively little pain |
WO2012009613A1 (en) | 2010-07-16 | 2012-01-19 | Seventh Sense Biosystems, Inc. | Low-pressure environment for fluid transfer devices |
US8641646B2 (en) | 2010-07-30 | 2014-02-04 | Cyberonics, Inc. | Seizure detection using coordinate data |
WO2012021801A2 (en) * | 2010-08-13 | 2012-02-16 | Seventh Sense Biosystems, Inc. | Systems and techniques for monitoring subjects |
US8684921B2 (en) | 2010-10-01 | 2014-04-01 | Flint Hills Scientific Llc | Detecting, assessing and managing epilepsy using a multi-variate, metric-based classification analysis |
WO2012064802A1 (en) | 2010-11-09 | 2012-05-18 | Seventh Sense Biosystems, Inc. | Systems and interfaces for blood sampling |
US9504390B2 (en) | 2011-03-04 | 2016-11-29 | Globalfoundries Inc. | Detecting, assessing and managing a risk of death in epilepsy |
US8428708B1 (en) | 2012-05-21 | 2013-04-23 | Incline Therapeutics, Inc. | Self-test for analgesic product |
US8428709B1 (en) * | 2012-06-11 | 2013-04-23 | Incline Therapeutics, Inc. | Current control for electrotransport drug delivery |
US9498162B2 (en) | 2011-04-25 | 2016-11-22 | Cyberonics, Inc. | Identifying seizures using heart data from two or more windows |
US9402550B2 (en) | 2011-04-29 | 2016-08-02 | Cybertronics, Inc. | Dynamic heart rate threshold for neurological event detection |
EP2701600B1 (en) | 2011-04-29 | 2016-06-08 | Seventh Sense Biosystems, Inc. | Delivering and/or receiving fluids |
WO2012149155A1 (en) | 2011-04-29 | 2012-11-01 | Seventh Sense Biosystems, Inc. | Systems and methods for collecting fluid from a subject |
US20130158468A1 (en) | 2011-12-19 | 2013-06-20 | Seventh Sense Biosystems, Inc. | Delivering and/or receiving material with respect to a subject surface |
US10448839B2 (en) | 2012-04-23 | 2019-10-22 | Livanova Usa, Inc. | Methods, systems and apparatuses for detecting increased risk of sudden death |
US9681836B2 (en) | 2012-04-23 | 2017-06-20 | Cyberonics, Inc. | Methods, systems and apparatuses for detecting seizure and non-seizure states |
NZ723391A (en) | 2012-08-31 | 2018-01-26 | Baxter Corp Englewood | Medication requisition fulfillment system and method |
EP3453377A1 (en) | 2012-10-26 | 2019-03-13 | Baxter Corporation Englewood | Improved work station for medical dose preparation system |
US9489489B2 (en) | 2012-10-26 | 2016-11-08 | Baxter Corporation Englewood | Image acquisition for medical dose preparation system |
US10220211B2 (en) | 2013-01-22 | 2019-03-05 | Livanova Usa, Inc. | Methods and systems to diagnose depression |
US20160045158A1 (en) * | 2013-03-15 | 2016-02-18 | Prometheon Pharma, Llc | Devices, systems, and methods for transdermal delivery of compounds |
NZ727697A (en) | 2014-06-30 | 2022-05-27 | Baxter Corp Englewood | Managed medical information exchange |
US11575673B2 (en) | 2014-09-30 | 2023-02-07 | Baxter Corporation Englewood | Central user management in a distributed healthcare information management system |
US11107574B2 (en) | 2014-09-30 | 2021-08-31 | Baxter Corporation Englewood | Management of medication preparation with formulary management |
WO2016090091A1 (en) | 2014-12-05 | 2016-06-09 | Baxter Corporation Englewood | Dose preparation data analytics |
AU2016226164A1 (en) | 2015-03-03 | 2017-10-19 | Baxter Corporation Englewood | Pharmacy workflow management with integrated alerts |
JP2018524718A (en) | 2015-06-25 | 2018-08-30 | ガンブロ・ルンディア・エービーGambro Lundia Ab | Medical device system and method with distributed database |
JP7153017B2 (en) | 2016-12-21 | 2022-10-13 | ガンブロ・ルンディア・エービー | A medical device system that includes an information technology infrastructure with a secure cluster domain that supports external domains |
Family Cites Families (21)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US3618601A (en) * | 1969-10-16 | 1971-11-09 | Thatcher W Richardson | Iontophoresis unit |
US4146029A (en) * | 1974-04-23 | 1979-03-27 | Ellinwood Jr Everett H | Self-powered implanted programmable medication system and method |
GB1553289A (en) * | 1975-05-23 | 1979-09-26 | Bacchelli S | Instrument for measuring body resistance |
US4141359A (en) * | 1976-08-16 | 1979-02-27 | University Of Utah | Epidermal iontophoresis device |
US4292968A (en) * | 1979-11-26 | 1981-10-06 | Sybron Corporation | Electric supply for ion therapy |
US4406658A (en) * | 1981-03-06 | 1983-09-27 | Medtronic, Inc. | Iontophoretic device with reversible polarity |
US4428378A (en) * | 1981-11-19 | 1984-01-31 | Medtronic, Inc. | Rate adaptive pacer |
US4704119A (en) * | 1983-02-03 | 1987-11-03 | Alza Corporation | Method comprising transdermal and buccal treatment of angina |
US4639244A (en) * | 1983-05-03 | 1987-01-27 | Nabil I. Rizk | Implantable electrophoretic pump for ionic drugs and associated methods |
US4808152A (en) * | 1983-08-18 | 1989-02-28 | Drug Delivery Systems Inc. | System and method for controlling rate of electrokinetic delivery of a drug |
FR2562800A1 (en) * | 1984-04-11 | 1985-10-18 | Fournier Laboratoires | Device for percutaneous administration of medicaments |
US4702732A (en) * | 1984-12-24 | 1987-10-27 | Trustees Of Boston University | Electrodes, electrode assemblies, methods, and systems for tissue stimulation and transdermal delivery of pharmacologically active ligands |
US4860751A (en) * | 1985-02-04 | 1989-08-29 | Cordis Corporation | Activity sensor for pacemaker control |
EP0461680A3 (en) * | 1985-06-10 | 1992-02-26 | Drug Delivery Systems Inc. | Programmable control and mounting system for transdermal drug applicator |
US4886489A (en) * | 1986-03-19 | 1989-12-12 | Jacobsen Stephen C | Flow-through methods and apparatus for iontophoresis application of medicaments at a controlled pH |
US4725263A (en) * | 1986-07-31 | 1988-02-16 | Medtronic, Inc. | Programmable constant current source transdermal drug delivery system |
US4822334A (en) * | 1986-12-04 | 1989-04-18 | Robert Tapper | Electrical dosimetry control system |
JPH02500339A (en) * | 1987-05-15 | 1990-02-08 | ニューマン,マーティン・エッチ | Ionosmotic drug supply device |
AU615188B2 (en) * | 1987-05-28 | 1991-09-26 | Drug Delivery Systems Inc. | Pulsating transdermal drug delivery system |
JPS6456060A (en) * | 1987-08-27 | 1989-03-02 | Hayashibara Takeshi | Low frequency medical treatment device |
US4942883A (en) * | 1987-09-29 | 1990-07-24 | Newman Martin H | Drug delivery device |
-
1991
- 1991-03-18 US US07/671,267 patent/US5213568A/en not_active Expired - Lifetime
- 1991-03-29 DE DE69121885T patent/DE69121885T2/en not_active Expired - Lifetime
- 1991-03-29 CA CA002079007A patent/CA2079007C/en not_active Expired - Lifetime
- 1991-03-29 JP JP50741491A patent/JP3300953B2/en not_active Expired - Lifetime
- 1991-03-29 AT AT91907606T patent/ATE142116T1/en not_active IP Right Cessation
- 1991-03-29 AU AU75868/91A patent/AU649439B2/en not_active Expired
- 1991-03-29 EP EP91907606A patent/EP0522062B1/en not_active Expired - Lifetime
-
1992
- 1992-09-29 FI FI924376A patent/FI111131B/en active
Cited By (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US20210212631A1 (en) * | 2011-01-10 | 2021-07-15 | Bodiguide Inc. | System and method for patient monitoring |
Also Published As
Publication number | Publication date |
---|---|
DE69121885D1 (en) | 1996-10-10 |
FI924376A (en) | 1992-09-29 |
EP0522062A1 (en) | 1993-01-13 |
AU7586891A (en) | 1991-10-30 |
ATE142116T1 (en) | 1996-09-15 |
EP0522062B1 (en) | 1996-09-04 |
CA2079007A1 (en) | 1991-10-01 |
FI924376A0 (en) | 1992-09-29 |
JPH05508558A (en) | 1993-12-02 |
FI111131B (en) | 2003-06-13 |
US5213568A (en) | 1993-05-25 |
DE69121885T2 (en) | 1997-03-20 |
JP3300953B2 (en) | 2002-07-08 |
AU649439B2 (en) | 1994-05-26 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CA2079007C (en) | Activity controlled electrotransport drug delivery device | |
CA2079462C (en) | Iontophoretic delivery device | |
CA2217711C (en) | Electrotransport delivery with voltage boosting circuit | |
US5697896A (en) | Electrotransport delivery device | |
US7212853B1 (en) | Electrotransport agent delivery method and apparatus | |
US5167616A (en) | Iontophoretic delivery method | |
WO1991015261A1 (en) | Activity controlled electrotransport drug delivery device | |
US7136698B2 (en) | Electrotransport agent delivery apparatus | |
EP1047475B1 (en) | Iontophoresis with programmed adjustment of electric current | |
CA2314929C (en) | Regulator with artificial load to maintain regulated delivery | |
NO321603B1 (en) | Apparatus for iontophoric delivery of drugs to a patient | |
CA2042994C (en) | Iontophoretic delivery device | |
AU710793B2 (en) | Electrotransport agent delivery method and apparatus |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
EEER | Examination request | ||
MKEX | Expiry |